Cereno Scientific Investor Relations Material
Latest events
CMD 2023
Cereno Scientific
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Cereno Scientific
Access all reports
Cereno Scientific AB (publ), a clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. The company is involved in developing CER-001, which is in Phase IIa study for the treatment of acute reperfused myocardial infarction; and Phase I/II study for amyotrophic lateral sclerosis patients. It has a collaboration with Oxford BioTherapeutics Ltd. to further advance the clinical development of CER-001 for the treatment of acute myocardial infarction; and strategic alliance with Novartis to develop tissue agnostic therapeutic treatments.
Key slides for Cereno Scientific
CMD 2023
Cereno Scientific
CMD 2023
Cereno Scientific
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden